Abpro Holdings Net Income From Continuing Ops Over Time
| ABP Stock | 1.86 0.04 2.11% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Abpro Holdings Performance and Abpro Holdings Correlation. Can Biotechnology industry sustain growth momentum? Does Abpro have expansion opportunities? Factors like these will boost the valuation of Abpro Holdings. If investors know Abpro will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Abpro Holdings demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Abpro Holdings's market price often diverges from its book value, the accounting figure shown on Abpro's balance sheet. Smart investors calculate Abpro Holdings' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since Abpro Holdings' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Abpro Holdings' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Abpro Holdings represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Abpro Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income From Continuing Ops Analysis
Compare Abpro Holdings and related stocks such as GeoVax Labs, BioLineRx, and Tharimmune Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GOVX | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (3.3 M) | (2.2 M) | (2.6 M) | (2.4 M) | (3 M) | (18.6 M) | (14 M) | (23.8 M) | (25 M) | (22.5 M) | (21.4 M) |
| BLRX | (17 M) | (17 M) | (17 M) | (17 M) | (11.1 M) | (14.4 M) | (15.8 M) | (24.4 M) | (23 M) | (25.4 M) | (30 M) | (27.1 M) | (25 M) | (60.6 M) | (9.2 M) | (8.3 M) | (8.7 M) |
| THAR | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (2.4 M) | (2.2 M) | (8.5 M) | (9.3 M) | (12.2 M) | (11 M) | (10.4 M) |
| APLM | (74.8 M) | (74.8 M) | (74.8 M) | (74.8 M) | (74.8 M) | (74.8 M) | (74.8 M) | (74.8 M) | (74.8 M) | (74.8 M) | (74.8 M) | (94.8 M) | (240.8 M) | (172.6 M) | (53.9 M) | (48.5 M) | (50.9 M) |
| AIMD | (617.4 K) | (617.4 K) | (617.4 K) | (617.4 K) | (617.4 K) | (617.4 K) | (617.4 K) | (617.4 K) | (1.3 M) | (1.6 M) | (1.5 M) | (3.9 M) | (14 M) | (10 M) | (14.9 M) | (13.4 M) | (12.7 M) |
| OSRH | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 403.8 K | (2.4 M) | (2.2 M) | (2.1 M) |
| LPCN | 76.7 K | 76.7 K | 76.7 K | (10.6 M) | (20.4 M) | (18.2 M) | (19 M) | (21 M) | (11.7 M) | (13 M) | (21 M) | (634.4 K) | (10.8 M) | (16.3 M) | 8.4 K | 9.6 K | 10.1 K |
| ADTX | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.8 M) | (9.1 M) | (46.4 M) | (27.6 M) | (32.4 M) | (35 M) | (31.5 M) | (33.1 M) |
| ICU | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (4.6 M) | (23 M) | (26.2 M) | (24.8 M) | (22.3 M) | (23.5 M) |
Abpro Holdings and related stocks such as GeoVax Labs, BioLineRx, and Tharimmune Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Abpro Holdings | ABP |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 68 Cummings Park |
| Exchange | New York Stock Exchange |
null 1.86
Additional Tools for Abpro Stock Analysis
When running Abpro Holdings' price analysis, check to measure Abpro Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abpro Holdings is operating at the current time. Most of Abpro Holdings' value examination focuses on studying past and present price action to predict the probability of Abpro Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abpro Holdings' price. Additionally, you may evaluate how the addition of Abpro Holdings to your portfolios can decrease your overall portfolio volatility.